Tumor-associated antigens and tumor-specific antigens presented by NGEN-181 allogeneic tumor cell vaccine

NGEN-181 is an investigational therapeutic cancer vaccine developed by NEUVOGEN, Inc., specifically targeting head and neck neoplasms (neuvogen.com). It is an allogeneic whole-cell vaccine that presents a diverse array of tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) to the patient's immune system (patsnap.com). These antigens are derived from multiple genetically modified allogeneic tumor cell lines, which are engineered to enhance the visibility of the cancer and broaden the immune response (neuvogen.com). By providing a library of cancer-specific signals, NGEN-181 aims to stimulate a robust, poly-specific T-cell response capable of eliminating both primary tumors and metastases (nih.gov). This approach is designed to overcome the challenges of tumor heterogeneity and immune escape that often limit the efficacy of single-antigen therapies (nih.gov). As an off-the-shelf product, it offers a more scalable and immediate treatment option compared to personalized autologous vaccines (livhospital.com). The vaccine is currently in preclinical development, with the goal of providing a safe and effective immunotherapy for patients with advanced head and neck cancers (patsnap.com). The antigens presented by the vaccine serve as the primary targets for the induced immune response, facilitating the recognition of malignant cells by cytotoxic T lymphocytes.

Other names

NGEN-181 TAAs/TSAsNeuvogen Head and Neck Cancer vaccine antigensHead and Neck Cancer TAAs (NGEN-181)NGEN-181 vaccine targets

NGEN-181 presents a broad library of tumor-associated and tumor-specific antigens to the patient's immune system, stimulating a poly-specific T-cell response against head and neck cancer cells (neuvogen.com).